|
|
journal of pharmaceutical sciences | 8 | ![](/images/barhorange.gif) | 5.00 |
fda.moph.go.th | 5 | ![](/images/barhorange.gif) | 3.12 |
¡ÒõÃǨàÍ¡Åѡɳì¾×ªÊÁعä¾Ã | 4 | ![](/images/barhorange.gif) | 2.50 |
ÁÍ¡. ¡ÃдÒÉà¢Õ¹ | 3 | ![](/images/barhorange.gif) | 1.88 |
à¡Å×Íä¹äµÃ·ì | 3 | ![](/images/barhorange.gif) | 1.88 |
Áҵðҹ¹éÓ´×èÁºÃèآǴ | 2 | ![](/images/barhorange.gif) | 1.25 |
§Ò¹ÇԨѾĵԡÃÃÁ¡ÒÃãªéÂÒã¹¼Ùé»èÇÂàºÒËÇÒ¹ | 2 | ![](/images/barhorange.gif) | 1.25 |
Í. | 2 | ![](/images/barhorange.gif) | 1.25 |
à·¤¹Ô¤¡ÒÃÍèÒ¹ÀÒÉÒÍѧ¡ÄÉà¾×èͤÇÒÁà¢éÒ㨠| 2 | ![](/images/barhorange.gif) | 1.25 |
âç¾ÂÒºÒÅÍÀÑÂÀÙàºÈà §Ò¹ºÃÔËÒÃàǪÀѳ±ì | 2 | ![](/images/barhorange.gif) | 1.25 |
Ẻ»ÃÐàÁÔ¹¤ÇÒÁàËÁÒÐÊÁ㹡ÒÃãªéÂÒ ceftazidime | 2 | ![](/images/barhorange.gif) | 1.25 |
ÂÒ | 2 | ![](/images/barhorange.gif) | 1.25 |
â»Ãá¡ÃÁ¨ÔµºÓºÑ´ in bipolar disorder | 2 | ![](/images/barhorange.gif) | 1.25 |
ÇÔ·Â ºÃÔ¡Òà ʶҺѹ ¸Ñ Ò ÃÑ¡Éì | 2 | ![](/images/barhorange.gif) | 1.25 |
ºÑµÃ»ÃЪҪ¹ãºà´ÕÂÇ | 2 | ![](/images/barhorange.gif) | 1.25 |
áʧÊèͧ㨠Íѹ´Ñº 1 | 2 | ![](/images/barhorange.gif) | 1.25 |
gmp âç§Ò¹ à¡ÕèÂǡѺ ¡ÒüÅÔµ¢¹Á»Ñ§ | 2 | ![](/images/barhorange.gif) | 1.25 |
µÅÒ´à¹×éÍâ¤ÃдѺÅèÒ§ | 2 | ![](/images/barhorange.gif) | 1.25 |
¾Ñ²¹Ò¡ÒÃà´ç¡ ¢Í§ ÊØÀÒÇ´Õ ËÒàÁ¸Õ »Õ 2532ºÃóҹءÃÁ | 2 | ![](/images/barhorange.gif) | 1.25 |
ÇѤ«Õ¹ eric | 2 | ![](/images/barhorange.gif) | 1.25 |
§Ò¹ÇԨѠâç¾ÂÒºÒÅÁËÒÃÒª¹¤ÃàªÕ§ãËÁèfull text | 2 | ![](/images/barhorange.gif) | 1.25 |
ÇÔ¸Õ¡ÒÃãªéËéͧÊÁØ´ | 2 | ![](/images/barhorange.gif) | 1.25 |
ÅѡɳеèÍÃèÒ§¡ÒÂcushing syndrome | 1 | ![](/images/barhorange.gif) | 0.62 |
¡¯¡ÃзÃǧ¤Çº¤ØÁà¡Å×ÍäÍâÍ´Õ¹ | 1 | ![](/images/barhorange.gif) | 0.62 |
»ÅÑ´¡ÃзÃǧÊÒ¸ÒóÊØ¢¤¹à¡èÒ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÈÙ¹ÂìÇԷºÃÔ¡Òà | 1 | ![](/images/barhorange.gif) | 0.62 |
ÃÙ»ÀÒ¾Á¡Ø®ÃÒª¡ØÁÒ÷ÑèÇâÅ¡ | 1 | ![](/images/barhorange.gif) | 0.62 |
lysergic acid diethylamide | 1 | ![](/images/barhorange.gif) | 0.62 |
thera vitae | 1 | ![](/images/barhorange.gif) | 0.62 |
ËÒ¤ÇÒÁ¨ØÎÒÃì´´ÔÊ | 1 | ![](/images/barhorange.gif) | 0.62 |
àÁç·â¸ÁÔÅ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÍÂèÒËŧàª×èÍ µ¡à»ç¹àËÂ×èÍ ¹Òâ¹ | 1 | ![](/images/barhorange.gif) | 0.62 |
âËÂè§àËÔ§ ËÅÍ¡Åǧ | 1 | ![](/images/barhorange.gif) | 0.62 |
á¹ÇÅÁ¾Ñ´ÊͺËÁÒ¶֧ | 1 | ![](/images/barhorange.gif) | 0.62 |
¶Ñ§àËÅç¡200ÅԵúÃèØÂÒ§ÁеÍ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÈعÂì·Ó¢Òà·ÕÂÁ ÀÒ¤ãµé | 1 | ![](/images/barhorange.gif) | 0.62 |
¡ÃзÃǧÊÒ¸ÒóÊØ¢ »ÃѺ°Ò¹à§Ô¹à´×͹¢éÒÃÒª¡Òà | 1 | ![](/images/barhorange.gif) | 0.62 |
áËÅ觷ÕèÁҢͧÊÒÃâ»áµÊà«ÕèÂÁ¤Íàõ | 1 | ![](/images/barhorange.gif) | 0.62 |
¡ÃÁÍØ·ÂÒ¹ "ÊÑÒ³´ÒÇà·ÕÂÁ" ¹¡ | 1 | ![](/images/barhorange.gif) | 0.62 |
àÊé¹àÅ×ʹᵡã¹á¡¹ÊÁͧ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÂÒʵÃÕ¹ÔÊÔ§àË ËÁÍÁÕ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÁÒµÃÒ°Ò¹¡ÒôÙáżÙé»èÇÂàºÒËÇÒ¹ | 1 | ![](/images/barhorange.gif) | 0.62 |
âç¾ÂÒºÒÅàÍ¡ª¹ àºÔ¡µÃ§ ¹¹·ºØÃÕ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÂÒʵÃÕà¾çÀÒ¤¡ÑºÊÔÇ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÊÁعä¾Ã ¢Ñ´ ˹éÒ ÊØÀÒ Àà ³ì | 1 | ![](/images/barhorange.gif) | 0.62 |
ÇÔ¸Õ»Ñé¹«ÙªÔ à»ç¹ÃٻǧÃÕ | 1 | ![](/images/barhorange.gif) | 0.62 |
ä¢éËÇÑ´Ê໹ | 1 | ![](/images/barhorange.gif) | 0.62 |
¼ÅÔµªÒÊÁعä¾Ã¼èÒ¹ ÍÂ. | 1 | ![](/images/barhorange.gif) | 0.62 |
ÂÒʵÃÕºÑÇá¡éÇ | 1 | ![](/images/barhorange.gif) | 0.62 |
ä¿âºÃÁÑÂÍÑÅà¨Õ | 1 | ![](/images/barhorange.gif) | 0.62 |
registry clean expert ¤×ÍÍÐäà | 1 | ![](/images/barhorange.gif) | 0.62 |
swot¡ÒúԹä·Â | 1 | ![](/images/barhorange.gif) | 0.62 |
thera vitae co.ltd | 1 | ![](/images/barhorange.gif) | 0.62 |
ª×èÍ ©ÅÒ¡ «ÕÍÔêÇ | 1 | ![](/images/barhorange.gif) | 0.62 |
national symposium on antimicrobial agent & resistance 2009 ËÃ×Í isaar 2009†| 1 | ![](/images/barhorange.gif) | 0.62 |
¿ÒÃìÁ¹éÍ¡ÅÒ§¢Ø¹à¢Ò | 1 | ![](/images/barhorange.gif) | 0.62 |
ʤº.¡Ñº¡ÒäØéÁ¤Ãͧ¼ÙéºÃÔâÀ¤ | 1 | ![](/images/barhorange.gif) | 0.62 |
ÂҾǡ nsaid | 1 | ![](/images/barhorange.gif) | 0.62 |
àÁÅÒÁÕ¹ äÁâ¤ÃàÇ¿ | 1 | ![](/images/barhorange.gif) | 0.62 |
»ÃСÒÈ ¡ÃзÃǧ ÊÒ¸ÒóÊØ¢ | 1 | ![](/images/barhorange.gif) | 0.62 |